- Filings
-
Holdings
-
Transcripts
- ETFs
- Insider
- Institutional
- Shorts
-
Profile
- Financials
Caribou Biosciences (CRBU)
Company Profile
Quarter (USD) | Mar 25 | Dec 24 | Sep 24 | Jun 24 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Dec 24 | Dec 23 | Dec 22 | Dec 21 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
---|---|---|---|---|---|---|
Cash on hand (at last report) | 29.46 mm | 29.46 mm | 29.46 mm | 29.46 mm | 29.46 mm | 29.46 mm |
Cash burn (monthly) | (no burn) | 1.67 mm | 14.30 mm | 13.63 mm | 12.24 mm | 11.48 mm |
Cash used (since last report) | n/a | 4.31 mm | 37.03 mm | 35.28 mm | 31.69 mm | 29.71 mm |
Cash remaining | n/a | 25.15 mm | -7.57 mm | -5.82 mm | -2.23 mm | -251.32 k |
Runway (months of cash) | n/a | 15.1 | -0.5 | -0.4 | -0.2 | -0.0 |
13F holders | Current |
---|---|
Total holders | 135 |
Opened positions | 25 |
Closed positions | 21 |
Increased positions | 47 |
Reduced positions | 27 |
13F shares | Current |
---|---|
Total value | 91.47 bn |
Total shares | 64.04 mm |
Total puts | 110.90 k |
Total calls | 151.50 k |
Total put/call ratio | 0.7 |
Largest owners | Shares | Value |
---|---|---|
BlackRock | 6.56 mm | $10.44 bn |
PFE Pfizer | 4.69 mm | $7.46 bn |
Vanguard | 4.57 mm | $7.26 bn |
Partner Fund Management | 3.88 mm | $6.16 bn |
Rachel E. Haurwitz | 3.35 mm | $20.50 mm |
MS Morgan Stanley | 2.75 mm | $4.37 bn |
Farallon Capital Partners | 2.58 mm | $41.11 mm |
JPM JPMorgan Chase & Co. | 2.50 mm | $3.97 bn |
Kynam Capital Management | 2.41 mm | $3.83 bn |
Schonfeld Strategic Advisors | 2.11 mm | $3.36 bn |
Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
---|---|---|---|---|---|---|---|---|---|---|
14 Mar 25 | Rachel E. Haurwitz | Common Stock | Buy | Acquire P | Yes | No | 1.02 | 20,000 | 20.40 k | 3,369,395 |
20 Feb 25 | Braunstein Scott | Option to purchase Common Stock Common Stock | Grant | Acquire A | No | No | 1.41 | 40,500 | 57.11 k | 40,500 |
20 Feb 25 | Guggenhime Andrew | Option to purchase Common Stock Common Stock | Grant | Acquire A | No | No | 1.41 | 40,500 | 57.11 k | 40,500 |
20 Feb 25 | Johnson David Lee | Option to purchase Common Stock Common Stock | Grant | Acquire A | No | No | 1.41 | 40,500 | 57.11 k | 40,500 |
20 Feb 25 | Natalie Sacks | Option to purchase Common Stock Common Stock | Grant | Acquire A | No | No | 1.41 | 40,500 | 57.11 k | 40,500 |